ER/PgR
Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial
The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.
TROPiCS-02 Trial Sees Progression-Free Survival Edge for Trodelvy-Treated Advanced Breast Cancers
The antibody-drug conjugate stretched out time to progression in a Phase III trial of pretreated patients with advanced hormone receptor-positive, HER2-negative breast cancers.
Sermonix Pharmaceuticals Begins Phase II Lasofoxifene Breast Cancer Trial
The company is studying lasofoxifene in combination with Eli Lilly's Verzenio in certain metastatic breast cancer patients with ESR1 mutations in their tumors.
Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and
Eli Lilly, Zentalis Pharma Partner to Study Selective Estrogen Receptor Degrader, Verzenio Combo
The two companies will evaluate the efficacy of the combination in patients with ER-positive, HER2-negative, advanced breast cancer.
Jun 12, 2020